Status Quo: US Approvals For Pepaxto, Copiktra Remain Intact Despite Negative Panel Reviews

 
• By Sue Sutter
  
Thumbs down
Pepaxto and Copiktra were knocked down at a September ODAC meeting, but they're still not completely out. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Post-Marketing Regulation & Studies

More from Product Reviews